1322625-54-6[2H]C([2H])([2H])C([2H])(C([2H])([2H])[2H])C([2H])(C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)N1CCCNC1=OKJHKTHWMRKYKJE-JOYHXWCXSA-N1322625-54-6Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungLopinavir-d8 is intended for use as an internal standard for the quantification of lopinavir by GC- or LC-MS. Lopinavir is a potent HIV-1 protease inhibitor (Ki = 1.3 pM for wild-type enzyme). It inhibits the replication of clinical isolates of HIV-1 (EC50s = 5-52 nM). Lopinavir reduces the infectious virus yield and viral RNA copy numbers in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50s = 26.63 and 26.10 μM, respectively). It reduces lung and kidney viral load, bronchointerstitial pneumonia, and pulmonary inflammatory cell infiltration in a marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered in combination with ritonavir .
VerwendenA labelled selective HIV protease inhibitor. An analogue of Ritonavir. Antiviral. It is a COVID19-related research product.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…